Sign in
Stories
RSV Vaccine Risk: GBS Concerns
Share
CDC Alerts on Rocky Mountain Spotted Fev...
CDC Expedites Release of Additional Dose...
Paxlovid's Effectiveness Under Scrutiny
CDC Revises COVID Guidelines
Covid-19 Vaccines in UK High Street Phar...
Ethris Initiates Virus-Induced Asthma Tr...
Overview
API
RSV vaccines from Pfizer and GSK for older adults may be linked to a higher risk of Guillain-Barré syndrome (GBS), based on data showing elevated GBS rates post-vaccination. The FDA noted an overrepresentation of GBS cases with Pfizer's Abrysvo. Despite uncertainties, CDC supports RSV vaccines' use in individuals over 60, with ongoing safety monitoring by both companies.
Ask a question
How can public health officials enhance the monitoring of adverse events related to vaccines like RSV, balancing benefits and risks?
What impact might this news have on public perception of RSV vaccines and vaccine uptake among the elderly population?
What measures can Pfizer and GSK implement to address the potential GBS risk while maintaining vaccine efficacy for older adults?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Dec 2023
Jan 2024
Feb 2024
Coverage